Journal article · 2026 · Open access
A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo
Nature Communications · Published 19 October 2026 · DOI 10.1038/s41467-026-78814-0
In brief
“A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo” is a 2026 journal article by Linda Julian and 37 co-authors, published in Nature Communications. OpenAlex counts 7 citations as of 17 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Communications.
- Citations
- 7
- Most cited in
- 2026 (4)
- Field-weighted impact
- 9.61
- References
- 113
- Authors
- 38
Abstract
The cyclin-dependent kinase CDK11 is an understudied kinase that has been the subject of conflicting reports regarding its function in cancer. Here, we combine genetic and pharmacological approaches to demonstrate that CDK11 is a critical regulator of cancer cell survival that is required for RNA splicing and the expression of homologous recombination genes. Inhibition of CDK11 disrupts genome stability, promotes the retention of intronic sequences in mature mRNAs, and induces synthetic lethality with PARP inhibitors. Through integrative analysis of functional genomics datasets, we identify heterozygous deletions of chromosome 1p36 - which encompasses CDK11 and its activating cyclin CCNL2 - as a recurrent and predictive biomarker of sensitivity to CDK11 inhibition. To assess the therapeutic potential of CDK11, we establish a genetically-engineered mouse model that allows us to differentiate between the on-target and off-target effects of CDK11 inhibitors in vivo. Using this platform, we demonstrate that MEL-495R, an orally bioavailable CDK11 inhibitor, induces widespread on-target toxicity, revealing a narrow therapeutic index. Experiments with a chemically distinct CDK11 inhibitor similarly reveal minimal anti-cancer activity at tolerable doses. Together, these findings define CDK11 as a core cancer dependency, uncover a chromosomal deletion that sensitizes tumors to CDK11 inhibition, demonstrate that on-target toxicity limits the efficacy of CDK11-targeting therapies, and provide a generalizable strategy for deconvolving drug efficacy and toxicity in vivo for novel oncology targets. CDK11 encodes a poorly-characterized cyclin-dependent kinase. Here, the authors demonstrate that CDK11 is essential for cancer proliferation, but the function(s) of CDK11 in normal tissue limits the efficacy of CDK11 inhibition as a therapeutic strategy.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Julian, L., Crozier, L., Lukow, D. A., Swamy, A., Mishra, S., Hagenson, R. A., Sennhenn, P. C., Sausville, E. L., McGeoch, A. J. S., Thompson, S. L., Mendelson, B. E., Chuaqui, C. E., Qiao, L., Vasudevan, A., Lin, K.-T., Bhatia, S., Bertomeu, T., Chatr‐aryamontri, A., Zhang, L., . . . Sheltzer, J. M. (2026). A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo. Nature Communications. https://doi.org/10.1038/s41467-026-78814-0
MLA 9
Julian, Linda, et al. “A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo.” Nature Communications, 2026. https://doi.org/10.1038/s41467-026-78814-0.
Chicago
Julian, Linda, Lisa Crozier, Devon A. Lukow, Aditi Swamy, Sanat Mishra, Ryan A. Hagenson, Peter C. Sennhenn, et al. 2026. “A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo.” Nature Communications. https://doi.org/10.1038/s41467-026-78814-0.
Harvard
Julian, L. et al. (2026) ‘A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo’, Nature Communications. doi:10.1038/s41467-026-78814-0.
IEEE
L. Julian et al., “A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo,” Nature Communications, 2026, doi: 10.1038/s41467-026-78814-0.
BibTeX
@article{julian2026genetic,
title = {{A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo}},
author = {Julian, Linda and Crozier, Lisa and Lukow, Devon A. and Swamy, Aditi and Mishra, Sanat and Hagenson, Ryan A. and Sennhenn, Peter C. and Sausville, Erin L. and McGeoch, Amy J. S. and Thompson, Sarah L. and Mendelson, Brianna E. and Chuaqui, Claudio E. and Qiao, Lu and Vasudevan, Anand and Lin, Kuan-Ting and Bhatia, Sonam and Bertomeu, Thierry and Chatr‐aryamontri, Andrew and Zhang, Li and Rees, Matthew G. and Ronan, Melissa M. and Roth, Jennifer A. and Nottoli, Timothy and Bai, Suxia and Lakshmipathi, Jayalakshmi and Muthusamy, Viswanathan and Van Vranken, Jonathan G. and Gauthier-Coles, Gregory and Gygi, Steven P. and Smith, Joan C. and others},
journal = {Nature Communications},
year = {2026},
doi = {10.1038/s41467-026-78814-0},
url = {https://doi.org/10.1038/s41467-026-78814-0}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- CDK11
- cyclin-dependent kinases
- on-target toxicity
- off-target effects
- synthetic lethality
- PARP inhibitors
- RNA splicing
- genome stability
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Julian, L., Crozier, L., Lukow, D. A., Swamy, A., Mishra, S., Hagenson, R. A., Sennhenn, P. C., Sausville, E. L., McGeoch, A. J. S., Thompson, S. L., Mendelson, B. E., Chuaqui, C. E., Qiao, L., Vasudevan, A., Lin, K.-T., Bhatia, S., Bertomeu, T., Chatr‐aryamontri, A., Zhang, L., . . . Sheltzer, J. M. (2026). A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo. Nature Communications. https://doi.org/10.1038/s41467-026-78814-0
How many times has this paper been cited?
7 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Communications: sign in and open the PDF from this page.
Who wrote this paper?
Linda Julian, Lisa Crozier, Devon A. Lukow, Aditi Swamy, Sanat Mishra, Ryan A. Hagenson, Peter C. Sennhenn, Erin L. Sausville, Amy J. S. McGeoch, Sarah L. Thompson, Brianna E. Mendelson, Claudio E. Chuaqui and 26 more.
What is the DOI of this paper?
10.1038/s41467-026-78814-0, permanently at https://doi.org/10.1038/s41467-026-78814-0. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.